Wolfgang Köenig
A5028480812- Lipoproteins and Cardiovascular Health
- Adipokines, Inflammation, and Metabolic Diseases
- High-Energy Particle Collisions Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Particle physics theoretical and experimental studies
- Quantum Chromodynamics and Particle Interactions
- Atherosclerosis and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Genetic Associations and Epidemiology
- Blood properties and coagulation
- Health Systems, Economic Evaluations, Quality of Life
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Blood Pressure and Hypertension Studies
- Cardiovascular Disease and Adiposity
- Diabetes and associated disorders
- Chronic Kidney Disease and Diabetes
- Air Quality and Health Impacts
- Climate Change and Health Impacts
- Particle Detector Development and Performance
- Cardiac Health and Mental Health
- Coronary Interventions and Diagnostics
- Inflammasome and immune disorders
- Liver Disease Diagnosis and Treatment
German Centre for Cardiovascular Research
2016-2025
Deutsches Herzzentrum München
2016-2025
Technical University of Munich
2016-2025
Universität Ulm
2016-2025
Zimmer Biomet (Germany)
2017-2025
GSI Helmholtz Centre for Heavy Ion Research
2015-2025
Helmholtz-Institute Ulm
2019-2024
Deutsches Herzzentrum der Charité
2016-2024
Nuffield Health
2024
Zimmer Biomet (United States)
2024
Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, inflammatory hypothesis atherothrombosis has remained unproved.We conducted a randomized, double-blind trial canakinumab, therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction high-sensitivity C-reactive protein level 2 mg or more per liter. The compared three doses canakinumab...
Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower as well cholesterol, we hypothesized that people with elevated but without hyperlipidemia might benefit from statin treatment.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Previous studies have shown that statin therapy reduces high-sensitivity C-reactive protein levels as well cholesterol, but no prospective trials directly addressed the issue of whether elevated are beneficial for apparently healthy persons with LDL cholesterol below current thresholds treatment. This randomized, double-blind, placebo-controlled, multicenter trial study was part Justification Use Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Study. The...
Experimental and clinical evidence supports the role of inflammation in atherosclerosis its complications. Colchicine is an orally administered, potent antiinflammatory medication that indicated for treatment gout pericarditis.
The natural history, management, and outcome of takotsubo (stress) cardiomyopathy are incompletely understood.The International Takotsubo Registry, a consortium 26 centers in Europe the United States, was established to investigate clinical features, prognostic predictors, cardiomyopathy. Patients were compared with age- sex-matched patients who had an acute coronary syndrome.Of 1750 cardiomyopathy, 89.8% women (mean age, 66.8 years). Emotional triggers not as common physical (27.7% vs....
Background —Inflammatory reactions in coronary plaques play an important role the pathogenesis of acute atherothrombotic events; inflammation elsewhere is also associated with both atherogenesis generally and its thrombotic complications. Recent studies indicate that systemic markers can identify subjects at high risk events. Methods Results —We used a sensitive immunoradiometric assay to examine association serum C-reactive protein (CRP) incidence first major heart disease (CHD) event 936...
Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing.We enrolled patients atherosclerotic cardiovascular disease (ORION-10 trial) and or an risk equivalent (ORION-11 who had elevated LDL despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned a 1:1 ratio to receive...
There is debate about the value of assessing levels C-reactive protein (CRP) and other biomarkers inflammation for prediction first cardiovascular events.We analyzed data from 52 prospective studies that included 246,669 participants without a history disease to investigate adding CRP or fibrinogen conventional risk factors risk. We calculated measures discrimination reclassification during follow-up modeled clinical implications initiation statin therapy after assessment fibrinogen.The...
<h3>Importance</h3> Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental lowering statin-treated patients; however, the effects these drugs on have not been evaluated. <h3>Objective</h3> To determine PCSK9 inhibition evolocumab patients. <h3>Design, Setting, and Participants</h3> The...
To help adapt cardiovascular disease risk prediction approaches to low-income and middle-income countries, WHO has convened an effort develop, evaluate, illustrate revised models. Here, we report the derivation, validation, illustration of charts that have been adapted circumstances 21 global regions.
BackgroundLow-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous disease.MethodsWe did a combined analysis of three large-scale sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, the UK Biobank). We characterised...
Recommendations for the use of cardiac troponin (cTn) measurement in acute care have recently been published.1 Subsequently, a high-sensitivity (hs) cTn T assay was introduced into routine clinical practice.2 This assay, as others, called highly sensitive, permits concentrations significant numbers apparently illness-free individuals. These assays can measure single digit range nanograms per litre (=picograms millilitre) and some research even allow detection 10% at 99th percentile URL...
It remains uncertain whether the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) reduce cardiovascular risk.To determine effects on outcomes of a carboxylic formulation EPA DHA (omega-3 CA) with documented favorable lipid inflammatory markers in patients atherogenic dyslipidemia high risk.A double-blind, randomized, multicenter trial (enrollment October 30, 2014, to June 14, 2017; study termination January 8, 2020; last patient visit May 2020) comparing CA corn oil...
Controversy persists regarding the extent of shared pathways between arterial and venous thrombosis whether treatments known efficacy for one disease process have consistent benefits other. Observational studies yielded variable estimates effect statin therapy on risk thromboembolism, evidence from randomized trials is lacking.We randomly assigned 17,802 apparently healthy men women with both low-density lipoprotein (LDL) cholesterol levels less than 130 mg per deciliter (3.4 mmol liter)...